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Letter to the Editor: Myelodysplastic Syndrome and 
Secondary Acute Leukemia After Treatment of Essential 
Throm bocythemia With Hydroxyurea 
We have read with interest the report of Toh et al. [ I ]  
on acute leukemia following treatment of polycythemia 
Vera and essential thrombocythemia (ET) with uracil 
mustard. One of their 16 ET patients treated by uracil 
mustard developed acute leukemia. The natural evolu- 
tion of ET into leukemia is a rare event, which may be 
accelerated by the use of alkylating agents or 32P ther- 
apy. Sedlacek et al. [2] and Gris et al. [3] recommend 
hydroxyurea as a relatively safe treatment modality for 
patients with ET. 
However, one of our patients with ET developed acute 
leukemia following treatment with hydroxyurea. A 45- 
year-old woman who underwent in 1968 a nephrectomy 
after irradiation with 30 Gy to the kidney area because of 
a Grawitz tumor developed ET and was treated over 7 
years with hydroxyurea, 1-2 g daily. Because of a per- 
sistent anemia, a bone marrow aspirate was taken in 
1989, and this revealed a hypercellular marrow, with 
marked dyserythropoiesis, dysgranulopoiesis, and 17% 
myeloblastic cells. Refractory anemia with excess of 
blasts was diagnosed according to the myelodysplastic 
syndromes classification of the FAB Cooperative Group 
[4]. Three months later, her WBC rose to 41 X 109/liter 
with 74% blast cells in the marrow. Acute myeloid leu- 
lating agents. She was irradiated 21 years before the onset 
of leukemia. Leukemias induced by irradiation have a 
high percentage of chromosomal abnormalities. Our pa- 
tient had no cytogenetic abnormalities. The frequency of 
leukemic transformation in untreated patients with ET is 
not known. Only long-term follow-up will establish 
whether hydroxyurea has less leukemogenic potential 
than alkylating agents and 32P in patients with ET. 
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